



Box 50

A

PATENT
Atty. Docket No.
CRP-141

Box Patent Application
Assistant Commissioner of Patents
Washington, D.C. 20231

NEW APPLICATION TRANSMITTAL

Transmitted herewith for filing is the patent application of
Inventor(s): Marc F. Charette.

WARNING: Patent must be applied for in the name(s) of all of the actual inventor(s). 37 CFR 1.41(a) and 1.53(b)

For (title): Methods and Compositions for Enhancing Cognitive Function Using
Morphogenic Proteins.

1. Type of Application

This new application is for a(n) (check one applicable item below):

- Original
- Design
- Plant

WARNING: Do not use this transmittal for a completion in the U.S. of an International Application under 35 U.S.C. 371(c)(4) unless the International Application is being filed as a divisional, continuation or continuation-in-part application.

NOTE: If one of the following 3 items apply then complete and attach ADDED PAGES FOR NEW APPLICATION TRANSMITTAL WHERE BENEFIT OF A PRIOR U.S. APPLICATION CLAIMED.

- Divisional
- Continuation
- Continuation-in-Part

CERTIFICATION UNDER 37 CFR 1.10

I hereby certify that this New Application Transmittal and the documents referred to as enclosed therein are being deposited with the United States Postal Service as Express Mail Label No. HB 159650722 in an Express Mail envelope addressed the Assistant Commissioner of Patents, Box Patent Application, Washington, D.C., 20231 on this 23rd day of January 1998.

Secretary

RUBIN D KELLY

NOTE: Each paper or fee referred to as enclosed herein has the number of the "Express Mail" mailing label placed thereon prior to mailing. 37 CFR 1.10(b)

New Application Transmittal

Page 2

2. Benefit of Prior U.S. Application(s) (35 USC 120)

NOTE: If the new application being transmitted is a divisional, continuation or a continuation-in-part of a parent case, or where the parent case is an International Application which designated the U.S., then check either the first option below or the second option below. If the second option is checked, the ADDED PAGES FOR NEW APPLICATION TRANSMITTAL WHERE BENEFIT OF PRIOR U.S. APPLICATION (S) IS CLAIMED must be completed and attached.

- The new application transmitted claims the benefit of prior U.S. application(s) and the priority information is contained in the enclosed new application
- The new application being transmitted claims the benefit of prior U.S. application(s) and enclosed are ADDED PAGES FOR NEW APPLICATION TRANSMITTAL WHERE BENEFIT OF PRIOR U.S. APPLICATION(S) CLAIMED.

**3. Papers Enclosed Which Are Required For Filing Date Under
37 CFR 1.53(b) (Regular) or 37 CFR 1.153 (Design) Application**

72 Pages of specification
4 Pages of claims
1 Pages of Abstract
4 Sheets of drawing

- formal
- informal

WARNING: DO NOT submit original drawings. A high quality copy of the drawings should be supplied when filing a patent application. The drawings that are submitted to the Office must be on strong, white, smooth, and nonshiny paper and meet the standards according to § 1.84. If corrections to the drawings are necessary they should be made to the original drawing and a high-quality copy of the corrected original drawing then submitted to the Office. Only one copy is required or desired. Comments on proposed new 37 CFR 1.84. Notice of March 9, 1988 (1990 O.G. 57-62).

NOTE: "Identifying indicia such as the serial number, group and unit, title of the invention, attorney's docket number, inventor's name, number of sheets, etc., not to exceed 2 3/4 inches (7.0cm.) in width may be placed in a centered location between the side edges within three fourths inch (19.1 mm.) of the top edge. Either this marking technique on the front of the drawing or the placement, although not preferred, of this information and the title of the invention on the back of the drawings is acceptable." Proposed 37 CFR 1.84(1). Notice of March 9, 1988 (1090 O.G.. 67-62).

4. Additional papers enclosed

- Preliminary Amendment
- Information Disclosure Statement
- Form PTO-1449
- Citations

New Application Transmittal
Page 3

- Declaration of Biological Deposit
- Submission of "Sequence Listing," computer readable copy and/or amendment pertaining thereto for biotechnology invention containing nucleotide and/or amino acid sequence.
- Authorization of Attorney(s) to Accept and Follow Instructions from Representative
- Special Comments
- Other

5. Declaration or oath

- Enclosed but unexecuted.
- Enclosed
 - executed by (check all applicable boxes)
 - inventor(s).
 - legal representative of inventor(s). 37 CFR 1.42 or 1.43
 - joint inventor or person showing a proprietary interest on behalf of inventor who refused to sign or cannot be reached.
 - this is the petition required by 37 CFR 1.47 and the statement required by 37 CFR 1.47 is also attached. See item 13 below for fee.
 - Not Enclosed.

WARNING: Where the filing is a completion in the U.S. of an International Application but where a declaration is not available or where the completion of the U.S. application contains subject matter in addition to the International Application the application may be treated as a continuation or continuation-in-part, as the case may be, utilizing ADDED PAGE FOR NEW APPLICATION TRANSMITTAL WHERE BENEFIT OF PRIOR U.S. APPLICATION CLAIMED.

- Application is made by a person authorized under 37 CFR 1.41(c) on behalf of all the above named inventor(s). The declaration or oath, along with the surcharge required by 37 CFR 1.16(e) can be filed subsequently.

NOTE: It is important that all the correct inventor(s) are named for filing under 37 CFR 1.41(c) and 1.53(b).

- Showing that the filing is authorized.
(Not required unless called into question. 37 CFR 1.41(d).

6. Inventorship Statement

WARNING: If the named inventors are each not the inventors of all the claims an explanation including the ownership of the various claims at the time the last claimed invention was made, should be submitted.

The inventorship for all the claims in this application are:

- The same
 - Are not the same. An explanation, including the ownership of the various claims at the time the last claimed invention was made,
 - Is submitted.
 - Will be submitted.

7. Language

NOTE: An application including a signed oath or declaration may be filed in a language other than English. A verified English translation of the non-English language application and the processing fee of \$130.00 required by 37 CFR 1.17(k) is required to be filed with the application or within such time as may be set by the Office. 37 CFR 1.52(d).

NOTE: A non-English oath or declaration in the form provided or approved by the PTO need not be translated. 37 CFR 1.69(b).

- English
 non-English

the attached translation is a verified translation. 37 CFR 1.52(d).

8. Assignment

- An assignment of the invention to
 is (are) attached. A separate "ASSIGNMENT COVER LETTER ACCOMPANYING NEW PATENT APPLICATION" is also attached.
 will follow.

NOTE: "If an assignment is submitted with a new application, send two separate letters - one for the application and one for the assignment." Notice of May 4, 1990 (1114D.G. 77-78).

9. Certified Copy

Certified copy(ies) of the application(s)

New Application Transmittal

Page 5



from which priority is claimed

- is (are) attached
- will follow.

NOTE: The foreign application forming the basis for the claim for priority must be referred to in the oath or declaration. 37 CFR 1.55(a) and 1.63.

NOTE: This item is for any foreign priority for which the application being filed directly relates. If any parent U.S. application or International Application from which this application claims benefit under 35 U.S.C.120 is itself entitled to priority from a prior foreign application then complete item 18 on the ADDED PAGES FOR NEW APPLICATION TRANSMITTAL WHERE BENEFIT OF PRIOR U.S. APPLICATION(S) CLAIMED.

10. Fee Calculation (37 CFR 1.16)

A. Regular application

CLAIMS AS FILED

	Number Filed	Number Extra		Rate	Basic Fee 37CFR 1.16(a) \$790.00
Total Claims (37 CFR 1.16 (c))	67	-20 = 47	X	\$ 22.00	\$1,034.00
Independent Claims (37 CFR 1.16 (b))	8	- 3 = 5	X	\$ 82.00	\$410.00
Multiple Dependent Claim(s), If any (37 CFR 1.16(d))	14		+	\$ 270.00	\$ 270.00

- Amendment canceling extra claims enclosed.
- Amendment deleting multiple-dependencies enclosed.
- Fee for extra claims is not being paid at this time.

NOTE. If the fees for extra claims are not paid on filing they must be paid or the claims canceled by amendment, prior to the expiration of the time period set for response by the Patent and Trademark Office in any notice of fee deficiency. 37 CFR 1.16(d).

Filing Fee Calculation \$2,504.00

B. Design application
(37 CFR 1.16(f))

Filing Fee Calculation \$ _____

C. Plant application
(\$510.00-37 CFR 1.16(g))

Filing Fee Calculation \$ _____

New Application Transmittal

Page 6

11. Small Entity Statement(s)

Verified Statement(s) that this is a filing by a small entity under 37 CFR 1.9 and 1.27 is (are) attached.

Filing Fee Calculation (50% of A, B or C above) \$ 1,252.00

NOTE: Any excess of the full fee paid will be refunded if a verified statement and a refund request are filed within 2 months of the date of timely payment of a full fee. 37 CFR 1.28(a).

12. Request for International-Type Search (37 CFR 1.104(d)) (complete, if applicable)

Please prepare an international-type search report for this application at the time when national examination on the merits takes place.

13. Fee Payment Being Made At This Time

Not Enclosed

No filing fee is to be paid at this time. (This and the surcharge required by 37 CFR 1.16(e) can be paid subsequently.)

Enclosed

basic filing fee \$ 1,252.00

recording assignment (\$40.00; 37 CFR 1.21(h)) \$ 40.00

petition fee for filing by other than all the inventors or person on behalf of the inventor where inventor refused to sign or cannot be reached (\$130.00; 37 CFR 1.47 and 1.17(h)) \$ _____

for processing an application with a specification in a non-English language. (\$130.00; 37 CFR 1.52(d) and 1.17(k)) \$ _____

processing and retention fee (\$130.00; 37 CFR 1.53(d) and 1.21(1)) \$ _____

fee for international-type search report (\$40.00; 37 CFR 1.21(e)). \$ _____

New Application Transmittal

Page 7

NOTE: 37 CFR 1.21(1) establishes a fee for processing and retaining any application which is abandoned for failing to complete the application pursuant to 37 CFR 1.53(d) and this, as well as the changes to 37 CFR 1.53 and 1.78, indicate that in order to obtain the benefit of a prior U.S. application, either the basic filing fee must be paid or the processing and retention fee of § 1.21(1) must be paid within 1 year from notification under § 53(d).

Total fees enclosed \$ 1,292.00

14. Method of Payment of Fees

- Check in the amount of \$ 1,292.00
- Charge Account No. _____ in the amount of \$ _____. A duplicate of this transmittal is attached.

NOTE: Fees should be itemized in such a manner that it is clear for which purpose the fees are paid. 37 CFR 1.22(b).

15. Authorization to Charge Additional Fees

WARNING: If no fees are to be paid on filing the following items should not be completed.

WARNING: Accurately count claims, especially multiple dependent claims, to avoid unexpected high charges, if extra claim charges are authorized.

- The Commissioner is hereby authorized to charge the following additional fees by this paper and during the entire pendency of this application to Account No.
 - 37 CFR 1.16(a),(f) or (g) (filing fees)
 - 37 CFR 1.16(b),(c) and (d)(presentation of extra claims)

NOTE: Because additional fees for excess or multiple dependent claims not paid on filing or on later presentation must only be paid for these claims canceled by amendment prior to the expiration of the time period set for response by the PTO in any notice of fee deficiency (37 CFR 1.16(d)), it might be best not to authorize the PTO to charge additional claim fees, except possibly when dealing with amendments after final action.

- 37 CFR 1.16(e) (surcharge for filing the basic filing fee and/or declaration on a date later than the filing date of the application)
- 37 CFR 1.17 (application processing fees)

WARNING: While 37 CFR 1.17(a), (b), (c) and (d) deal with extensions of time under § 1.136(a) this authorization should be made only with the knowledge that "Submission of the appropriate extension fee under 37 C.F.R. 1.136(a) is to no avail unless a request or petition for extension is filed." (Emphasis added). Notice of November 5, 1985 (1060 OG. 27).

- 37 CFR 1.18 (issue fee at or before mailing of Notice of Allowance, pursuant to 37 CFR 1.311(b))

New Application Transmittal

Page 8

NOTE: Where an authorization to charge the issue fee to a deposit account has been filed before the mailing of a Notice of Allowance, the issue fee will be automatically charged to the deposit account at the time of mailing the notice of allowance, 37 CFR 1.31(b).


NOTE: 37 CFR 1.28(b) requires "Notification of any change in loss of entitlement to small entity status must be filed in the application... prior to paying, or at the time of paying... issue fee". From the wording of 37 CFR 1.28(b): (a) notification of change of status must be made even if the fee is paid as "other than a small entity" and b) no notification is required if the change is to another small entity.

16. Instructions As To Overpayment

Credit Account No. 033567

refund

January 22, 1998
Creative BioMolecules, Inc.
101 Huntington Avenue, Ste. 2400
Boston, MA 02199
Tel. No. 617/492-2988


Robin D. Kelley
Reg. No. 34,637
Attorney for Applicants

**New Application Transmittal
Page 9**

Incorporation by reference of added pages

Check the following item if the application in this transmittal claims the benefit of prior U.S. application(s) (including an international application entering the U.S. stage as a continuation, divisional or C-I-P application) and complete and attach the ADDED PAGES FOR NEW APPLICATION TRANSMITTAL WHERE BENEFIT OF PRIOR U.S. APPLICATION(S) CLAIMED

Plus Added Pages For New Application Transmittal Where Benefit of prior U.S.

Application(s) Claimed _____
Number of pages added _____

Plus Added Pages For Papers Referred To In Item 4 Above

Number of pages added _____

Plus "Assignment Cover Letter Accompanying New Application"

Number of pages added _____

Statement Where No Further Pages Added

(if no further pages form a part of this Transmittal then end this Transmittal with this page and check the following item)

This transmittal ends with this page.

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant or Patentee **Marc F. Charette**.


Serial or Patent No.:

Filed or Issued: **Filed on Even Date Herewith**

For: **Methods and Compositions for Enhancing Cognitive Function Using Morphogenic Proteins**

CERTIFICATION UNDER 37 CFR 1.10

I hereby certify that this New Application Transmittal and the documents referred to as enclosed therein are being deposited with the United States Postal Service as Express Mail Label No. HB159650722 in an Express Mail envelope addressed the Assistant Commissioner of Patents, Box Patent Application, Washington, D.C., 20231 on this 23rd day of January 1998.


ROBIN D. KELLY

**VERIFIED STATEMENT (DECLARATION) CLAIMING SMALL ENTITY
STATUS (37 CFR 1.9(f) AND 1.27(c)) - SMALL BUSINESS CONCERN**

I hereby declare that I am

- the owner of the small business concern identified below;
- an official of the small business concern empowered to act on behalf of the concern identified below:**

NAME OF CONCERN: **CREATIVE BIOMOLECULES, INC**

ADDRESS OF CONCERN: **101 Huntington Avenue, Ste. 2400, Boston, MA 02199**

I hereby declare that the above identified small business qualifies as a small business concern as defined in 13 CFR 121.3-18, and reproduced in 37 CFR 1.9(d), for purposes of paying reduced fees under Section 41(a) and (b) of Title 35, United States Code, in that the number of employees of the concern, including those of its affiliates, does not exceed 500 persons. For purposes of this statement, (1) the number of employees of the business concern is the average over the previous fiscal year of the concern of the persons employed on a full-time, part-time or temporary basis during each of the pay periods of the fiscal year, and (2) concerns are affiliates of each other when either, directly or indirectly, one concern controls or has the power to control the other, or a third-party or parties controls or has the power to control both.

I hereby declare that rights under contract or law have been conveyed, to and remain with the small business concern identified above with regard to the invention, entitled

Methods and Compositions for Enhancing Cognitive Function Using Morphogenic Proteins

by inventor(s) Marc F. Crastite
described in

the specification filed herewith.

- application serial no. 0 ____ / ____ filed _____.
 patent no. _____ issued _____.

Verified Statement (Declaration) claiming Small Entity Status (37 CFR 1.9(f) and 127(c)) -Small Business Concern

Page 2

If the rights held by the above identified small business concern are not exclusive, each individual, concern or organization having rights to the invention listed below* and no rights to the invention are held by any person, other than the inventor, who could not qualify as a small business concern under 37 CFR 1.9(d) or by any concern which would not qualify as a small business concern 37 CFR 1.9(d) or a nonprofit organization under 37 CFR 1.9(e).

*NOTE: Separate verified statements are required for each named person, concern or organization having rights to the invention averring to their status as small entities (37 CFR 1.27).

NAME _____
ADDRESS _____

INDIVIDUAL SMALL BUSINESS CONCERN NONPROFIT ORGANIZATION

NAME _____
ADDRESS _____

INDIVIDUAL SMALL BUSINESS CONCERN NONPROFIT ORGANIZATION

I acknowledge the duty to file, in this application or patent, notification of any change in status resulting in loss of entitlement to small entity status prior to paying, or at the time of paying, the earliest of the issue fee or any maintenance fee due after the date on which status as a small business entity is no longer appropriate. (37 CFR 1.28(b)).

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application, any patent issuing thereon, or any patent to which this verified statement is directed.

NAME OF PERSON SIGNING Cheryl K. Lawton, Esq.

TITLE OF PERSON OTHER THAN OWNER Vice-President

ADDRESS OF PERSON SIGNING 101 Huntington Ave., Suite 2400, Boston, MA 02199

SIGNATURE Cheryl K. Lawton Date 1/22/98